Luke Wittenburg
5PUBLICATIONS
9CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Feb 20, 2026
Tolerability and Adverse Event Profile of Fixed Dose Rate Gemcitabine in Dogs With Neoplasia.Evangelia J Makrygiannis, Luke Wittenburg, Carlos O Rodriguez
|Dec 11, 2022
Microglia-Derived Olfactomedin-like 3 Is a Potent Angiogenic Factor in Primary Mouse Brain Endothelial Cells: A Novel Target for Glioblastoma.Laila M Joseph, Ryan G Toedebusch, Eshetu Debebe
|Sep 03, 2022
Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma.Sridhar Veluvolu, Jennifer L Willcox, Katherine A Skorupski
|Aug 06, 2019
The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.Fernando Alegre, Amanda R Ormonde, Dayn R Godinez
|Jan 15, 2019
Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.Luke A Wittenburg, Kristen Weishaar, Dominique Ramirez
Pageof 1
Frequent Collaborators
2 joint publications
Katherine A Skorupski
2 joint publications
Robert Rebhun
1 joint publications
Fernando Alegre
1 joint publications
Xinbin Chen
1 joint publications
Christine M Toedebusch
1 joint publications
Jennifer L Willcox
1 joint publications
Sami Al-Nadaf
1 joint publications
Evangelia J Makrygiannis
1 joint publications
Amandine T Lejeune
